Platelet aggregation, the process by which platelets adhere to each other at sites of vascular injury, is important for hemostatic plug formation and thrombosis. Platelet aggregation devices are often used to treat cardiovascular and bleeding disorders. Platelet function tests are used to measure the ability of platelets to aggregate and promote clotting in the sample of blood. A variety of tests are available but there is no one test that identifies all problems with platelet function.

Market Statistics:

The Global Platelet Aggregation Devices Market is estimated to account for US$ 549.0 Mn in terms of value by the end of 2022.


Increase in use of or increase in demand for platelet aggregation devices is expected to propel the growth of the global platelet aggregation devices market over the forecast period. For instance, the growing burden of bleeding disorders has increased the demand for platelet aggregation systems, as they are used for the diagnosis of bleeding disorders. In July 2021, Sysmex Europe announced the launch of two new automated blood coagulation analyzers, CN-3500 and CN-6500, in specific countries in the EMEA (Europe, the Middle East, and Africa) region. They are targeted at medium- and large-scale hospitals and commercial labs, as well as other facilities.


Increase in burden of cardiovascular diseases (CVDs) and growing geriatric population across the globe is expected to provide significant growth opportunities for players in the platelet aggregation devices market. For instance, the aging or elderly population are particularly susceptible to CVDs. Adults age 65 and older are more likely to suffer from cardiovascular disease than younger people. According to the Centers for Disease Control and Prevention (CDC), around 85% of older adults in the U.S. have at least one chronic health condition, and 60% have at least two chronic conditions. This in turn is expected to increase demand for platelet aggregation devices.


Shortage of skilled personnel and high cost of such devices are major factors expected to hamper growth of the global platelet aggregation devices market. For instance, although new technologies, systems, or devices are having profound impact on patients, doctors, and healthcare organizations, the medical workforce (skilled personnel) falls short as a career choice for many reasons, which in turn leads to the current shortage of skilled personnel. This is one of the significant challenges faced by the platelet aggregation devices market, restraining the market growth.

Global Platelet Aggregation Devices Market - Impact of Coronavirus (Covid-19) Pandemic:

Platelet aggregation devices/systems are used to treat cardiovascular and bleeding diseases, but the outbreak of COVID-19 has had a severe impact on the treatment of these diseases and the supply chain of the devices across the world. However, increasing research related to platelet aggregation on the human platelet cells involved in COVID-19 is expected to aid in the growth of the platelet aggregation devices market.

To know the latest trends and insights prevalent in this market, click the link below:

Key Takeaways:

The global platelet aggregation devices market was valued at US$ 518.7 Mn in 2021 and is forecast to reach a value of US$ 794.0 Mn by 2028 at a CAGR of 6.3% between 2022 and 2028.

Among product, reagent segment held dominant position in the global platelet aggregation devices market in 2021, accounting for 61.9% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.

Market Trends:

With continuous advances in the field of platelet aggregation devices, the market for aggregation devices/systems is expected to grow over the forecast period. As these advancements have reached clinical use, demand for these devices has increased. Moreover, further future improvements and developments are also expected increase the demand for platelet aggregation devices/systems. This trend is expected to continue during the forecast period, driving the growth of the market.

Competitive Landscape:

Major players operating in the global platelet aggregation devices market include WerfenLife SA, Siemens Healthineers, Sysmex Corporation, Sentinel Ch. SpA, Haemonetics Corporation, Chrono-Log Corporation, Bio/Data Corporation, Aggredyne Inc., F. Hoffmann-La Roche Ltd., and Helena Laboratories Corporation, among others.

Recent Developments:

In March 2020, Hart Bio announced the launch of ADP MEA and TRAP-6 MEA. Both ADP MEA and TRAP-6 MEA are designed to monitor and test platelet aggregation function of patients. ADP MEA is designed for use in diagnosing platelet dysfunction or normal platelet activity in whole blood for Multiple Electrode Aggregometry.

In April 2018, Stago launched a compact platelet aggregation system for the faster exploration and evaluation of platelet function in citrated platelet-rich plasma. TA-8V and TA-4V, bring specialist testing for potential platelet disorders closer to the patient, which in turn helps speed the diagnostic pathway while saving laboratory time and costs.


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo